Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in New Zealand has been experiencing steady growth in recent years.
Customer preferences: Patients suffering from rheumatic diseases in New Zealand are increasingly seeking more personalized and effective treatments. They are also becoming more aware of the available treatment options and are willing to try new drugs that have proven to be effective in other countries. Additionally, patients are looking for treatments that can help them manage their symptoms and improve their quality of life.
Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in New Zealand is the increasing use of biologic drugs. Biologic drugs are becoming more popular due to their effectiveness in treating rheumatic diseases and their ability to target specific parts of the immune system. Another trend is the growing use of combination therapies, which involve the use of two or more drugs to achieve better outcomes. This approach is gaining popularity as it allows for more personalized treatment plans that can be tailored to individual patients.
Local special circumstances: New Zealand has a relatively small population, which means that the market for Anti-Rheumatic Drugs is also relatively small. This presents a challenge for pharmaceutical companies as they have to balance the cost of developing and marketing new drugs with the potential revenue from the New Zealand market. Additionally, the New Zealand government has a strict regulatory framework for drug approval, which can make it difficult for new drugs to enter the market.
Underlying macroeconomic factors: The New Zealand healthcare system is publicly funded, which means that patients have access to subsidized healthcare. However, the government has been facing increasing pressure to reduce healthcare spending, which has led to a focus on cost-effective treatments. This has put pressure on pharmaceutical companies to develop drugs that are not only effective but also cost-effective. Additionally, the aging population in New Zealand is expected to increase the demand for Anti-Rheumatic Drugs in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
